Bexarotene

Bexarotene
Clinical data
Trade names	Targretin
AHFS/Drugs.com	Monograph
MedlinePlus	a608006
License data	EU EMA: by INN; US DailyMed: Bexarotene; US FDA: Bexarotene;
Routes of; administration	By mouth, topical
ATC code	L01XF03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C2 (Retinoids); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	>99%
Metabolism	Hepatic (CYP3A4-mediated)
Elimination half-life	7 hours
Excretion	Parent drug and metabolites are eliminated primarily through the hepatobiliary system. Less than 1% is excreted in the urine unchanged.
Identifiers
	IUPAC name 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic acid;
CAS Number	153559-49-0 ;
PubChem CID	82146;
IUPHAR/BPS	2807;
DrugBank	DB00307 ;
ChemSpider	74139 ;
UNII	A61RXM4375;
KEGG	D03106;
ChEBI	CHEBI:50859 ;
ChEMBL	ChEMBL1023 ;
CompTox Dashboard (EPA)	DTXSID1040619 ;
ECHA InfoCard	100.206.790
Chemical and physical data
Formula	C24H28O2
Molar mass	348.486 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)c1ccc(cc1)C(/c2c(cc3c(c2)C(CCC3(C)C)(C)C)C)=C;
	InChI InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26) ; Key:NAVMQTYZDKMPEU-UHFFFAOYSA-N ;
	(verify)

Bexarotene, sold under the brand Targretin, is an antineoplastic (anti-cancer) agent used for the treatment of cutaneous T cell lymphoma (CTCL). It is a third-generation retinoid.

It was approved by the U.S. Food and Drug Administration (FDA) in December 1999, and the European Medicines Agency (EMA) in March 2001. It is available as a generic medication.